Answers are grounded in this paper and cite their sources.
Objectives: In children, high-grade gliomas are less common than low-grade gliomas, accounting for 3-15% of primary central nervous system tumors. Mismatch repair (MMR) deficiency is established in colonic and endometrial tumors. However, its prevalence in gliomas varies widely in the literature, ranging from 0% to 44%. Most of them are more prevalent in pediatric compared to adult gliomas. We aimed to assess the prevalence of MMR status in pediatric gliomas using immunohistochemistry (IHC), followed by their distribution with isocitrate dehydrogenase (IDH1) mutation status and clinicopathological profile at a tertiary care center. Materials and Methods: This is a cross-sectional study done over 6 years at a tertiary care center that reviewed all pediatric glioma cases (grades 2–4). IHC for IDH1 and MMR proteins (MLH1 (mutL homolog 1), MSH2 (mutS homolog 2), PMS2 (post meiotic segregation increased 2), and MSH6 (mutS homolog 6)) was performed, with loss of any MMR protein indicating MMR deficiency. We analyzed the prevalence of MMR deficiency, its correlation with IDH1 mutation, and clinicopathological features. Programmed cell death ligand 1 (PD-L1) IHC was also done in five MMR-deficient cases to assess tumor proportion score (TPS). Results: The study cohort included 18 patients (median age 12.9 years; male-to-female ratio 0.8:1). MMR deficiency was found in 5/18 cases (27.8%), most commonly involving MSH6 (3/5, 60%) and MSH2 (2/5, 40%). Among IDH1-mutant gliomas, 1/3 (33.3%) showed MMR deficiency, while 4/15 (26.6%) were IDH1 wild type. MMR deficiency was frequent in pediatric diffuse high-grade glioma, not otherwise specified (NOS) (2/10, 20%), and pleomorphic xanthoastrocytoma (2/4, 50%). Giant cells were seen in 2/5 (40%) MMR-deficient gliomas. PD-L1 was positive (TPS ≥5%) in one of five MMR-deficient cases. Conclusion: IHC is a valuable tool for assessing MMR mutations in gliomas. Identifying these mutations is crucial for tailoring treatment strategies, as MMR-deficient gliomas are resistant to standard therapies, and for offering genetic counseling, family screening, and understanding prognostic implications.
No takes yet. Share an insight, caveat, or question.
Srinivasan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: